Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2020-07-08 AGM Information
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
CYC 2020 AGM Presentation 29 pages 7.1MB
AGM Information Classification · 95% confidence The document is titled 'AGM Presentation 2019 Financial Year Results 9 July 2020' and contains detailed presentation slides including Chairman's and Managing Director's addresses, financial highlights for FY2019, operational highlights, strategic priorities, and clinical trial updates. The content is structured as a presentation given at the Annual General Meeting (AGM) focusing on financial results and company strategy. There is no indication that this is the full Annual Report or a regulatory filing, but rather a presentation material shared during the AGM. Therefore, the document fits the category of AGM Information (AGM-R). The document length (15,000 characters) and detailed content support this classification with high confidence.
2020-07-08 English
Managing Director's Address to Shareholders 7 pages 254.3KB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by the Managing Director of Cyclopharm Ltd, discussing the company's 2019 financial performance, strategic priorities, operational highlights, and future growth opportunities. It includes slides with financial data, market expansion plans, regulatory updates (such as USFDA approval progress), and clinical initiatives. The content is structured as a presentation with slides and addresses investors and shareholders, focusing on financials, strategy, and market position. There is no indication that this is a full annual report or regulatory filing, nor is it a transcript of a call or an announcement of voting results. The presence of slides and the nature of the content strongly suggest this is an Investor Presentation (IP). The document length (15,000 characters) and detailed financial and strategic information support this classification with high confidence.
2020-07-08 English
Results of Meeting 2 pages 143.6KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement dated 9 July 2020 from Cyclopharm Ltd regarding the results of their Annual General Meeting (AGM). It includes detailed voting results for resolutions passed at the AGM, such as adoption of the remuneration report, re-election of a director, and issue of shares to the managing director. The document references compliance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, which relate to disclosure of voting results. The content is focused on the official results of shareholder votes at the AGM, not the AGM materials themselves or the full annual report. The document length is 3240 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-07-08 English
CYC 1H2020 Business Update 6 pages 215.2KB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed business update from Cyclopharm Limited for the first half of the financial year 2020. It includes financial performance data such as revenue, gross margin, cash balances, and capital raising details. It also discusses operational matters including progress on USFDA approval, litigation updates, joint ventures, and new growth opportunities. The document contains substantive financial data and analysis for a half-year period, indicating it is a comprehensive interim report rather than a brief announcement or presentation. The length (15,000 characters) and content confirm it is not a short announcement or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-07-06 English
Notice of Annual General Meeting/Proxy Form 22 pages 1.5MB
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting and Explanatory Statement' for Cyclopharm Limited, detailing the date, time, and procedures for the AGM scheduled on 9 July 2020. It includes the agenda, resolutions to be voted on (such as the Remuneration Report, re-election of a director, and issue of shares to the Managing Director), proxy voting instructions, and explanatory notes. The document is clearly a notice and explanatory material for the AGM, not the actual Annual Report or financial statements themselves. It is a formal communication to shareholders to inform them about the meeting and solicit their votes. Therefore, this document fits the category of AGM Information (AGM-R).
2020-06-04 English
Technegas Approved in Russia - Clarification 1 page
Regulatory Filings Classification · 95% confidence The document is a short announcement from Cyclopharm Limited regarding clarification on a previous announcement about the approval of Technegas in Russia. It is addressed to the Australian Securities Exchange and includes contact information and a brief description of the company and product. There are no financial statements, detailed financial data, or comprehensive report content. The document is under 5,000 characters and serves as a clarification or update rather than a full report or detailed filing. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2020-05-28 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.